An anticoagulant heparin oligosaccharide phenyl dimer and its preparation method and application

Synthesis of anticoagulant heparin oligosaccharide phenyldimer by chemical enzyme method has solved the problems of low anticoagulant activity and high HIT risk of existing anticoagulant drugs, achieved efficient and safe anticoagulant effects, and passed the fish Protamine neutralization characteristics enhance clinical application value.

CN116120484BActive Publication Date: 2024-11-08SHANDONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211066891.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-09-01
Publication Date
2024-11-08
Estimated Expiration
2042-09-01

AI Technical Summary

Technical Problem

The existing anticoagulant heparin drugs have problems such as generally low anticoagulant activity, large side effects, short half-life in the body, and high risk of adverse HIT reactions. The poor neutralization efficiency of protamine limits its clinical application.

Method used

The anticoagulant heparin oligosaccharide phenyldimer was synthesized by chemical enzyme method, and a novel heparin oligo with significant anti-Xa activity and can be efficiently neutralized by protamine through specific glycosyltransferase catalytic reaction and sulfation modification. Glycophenylbidimer, which combines AT binding sequence, achieves optimization of pharmacokinetic characteristics.

Benefits of technology

Achieve efficient and safe anticoagulation effect, long half-life in vivo, high bioavailability, low HIT risk, and the protamine neutralization characteristics with long-chain heparin analogs are significantly lower than those of commercially available drugs, and have important clinical applications value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116120484B_ABST
    Figure CN116120484B_ABST
Patent Text Reader

Abstract

The present invention relates to an anticoagulant heparin oligosaccharide phenyl dimer and a preparation method and application thereof, which has a structure as shown in general formula I, and the benzene ring can be replaced by a substituted phenyl, an aromatic heterocycle or a substituted aromatic heterocycle. The heparin oligosaccharide phenyl dimer of the present invention has a small number of synthetic steps and a significantly high total yield, has a strong and specific anti-Xa factor activity dependent on antithrombin, has no obvious anti-IIa activity, and the anticoagulant activity can be efficiently neutralized by protamine, and has excellent pharmacokinetic characteristics, so it is suitable for preparing a new anticoagulant and antithrombotic drug with cost advantages, better quality and safety. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to an anticoagulant heparin oligosaccharide phenyl dimer and a preparation method and application thereof, belonging to the technical field of biomedicine. Background Art

[0002] Heparin is an ancient natural polysaccharide anticoagulant, which is still widely used in clinical indications such as thromboembolic diseases, myocardial infarction, cardiovascular surgery, cardiac catheterization, extracorporeal circulation, and hemodialysis. The global market size has reached 8 billion US dollars and is growing. The current commercial natural heparin drugs mainly include unfractionated heparin (UFH) extracted from porcine small intestinal mucosa and different low-molecular-weight heparins (LMWH) obtained by chemical or enzymatic partial depolymerization. LMWH drugs have gradually surpassed UFH to become the first choice of clinical anticoagulant drugs due to their advantages such as long half-life in vivo, high bioavailability, few side effects and safe use, but their anticoagulant activity is generally lower than that of UFH. UFH and LMWH derived from animal tissues, in addition to impurity contamination and fragile raw material supply chain, are highly sulfated glycosaminoglycans. Their variable sulfation, isomerization and other modifications are unevenly distributed along the sugar chain, forming a highly complex and heterogeneous fine structure, which leads to their insurmountable clinical limitations.

[0003] Studies have shown that the common structural basis for the anticoagulant effect of UFH and LMWH is the unique pentasaccharide sequence in the heparin chain that specifically binds to antithrombin (AT) (abbreviated as: GlcNS / Ac6S-GlcA-GlcNS6S3S-IdoA2S-GlcNS6S), and its methyl glycoside derivative, fondaparinux sodium (trade name ) was successfully launched in 2001 and is the only fully synthetic single heparin compound approved for marketing so far. However, although fondaparinux sodium has excellent clinical anticoagulant therapeutic effects, its anti-Xa activity cannot be neutralized by protamine like animal-derived heparin, and anticoagulant therapy cannot be terminated according to the course of treatment, effectively avoiding adverse reactions such as bleeding, which has led to significant limitations in its clinical application. Therefore, the development of new anticoagulant heparin molecules that can be neutralized by protamine has important clinical value.

[0004] However, although protamine has a long history as a reversal agent for animal-derived heparin in clinical practice, its research is not systematic and in-depth enough. It is generally believed that the neutralization efficiency of protamine is jointly determined by the length, charge density and distribution of heparin. For example, Professor Jian Liu of the United States used a chemical enzyme method to synthesize a heparin dodecasaccharide containing a single AT-bound pentasaccharide and four consecutive trisulfate disaccharides (IdoA2S-GlcNS6S). Its anticoagulant activity can be effectively neutralized by protamine, and it is widely believed that the anticoagulant heparin dodecasaccharide containing four trisulfate disaccharides is the smallest heparin molecule that can be neutralized by protamine. However, the synthesis steps of the above-mentioned neutralizable anticoagulant heparin dodecasaccharide are 22 to 23 steps, the steps are cumbersome, the cost is high, the total yield is low, and its half-life in vivo is short, and there are potential adverse reactions such as HIT. Summary of the invention

[0005] In view of the deficiencies in the prior art, the present invention provides an anticoagulant heparin oligosaccharide phenyl dimer and a preparation method and application thereof.

[0006] Terminology Note:

[0007] AT: Antithrombin

[0008] UDP-GlcNTFA: Uridine diphosphate-N-trifluoroacetylglucosamine

[0009] UDP-GlcNAc: Uridine diphosphate-N-acetylglucosamine

[0010] UDP-GlcA: uridine diphosphate-glucuronic acid

[0011] PAPS: 3'-phosphoadenosine-5'-phosphosulfate.

[0012] KfiA: Escherichia coli K5 N-acetylglucosaminyltransferase

[0013] PmHS2: Pasteurella multocida heparosan synthase 2

[0014] NST: N-sulfatase

[0015] C5-epi: C5-isomerase

[0016] 2OST: 2-O-sulfotransferase

[0017] 6OST: 6-O-sulfatase

[0018] 3OST: 3-O-sulfotransferase

[0019] The technical solution of the present invention is as follows:

[0020] The first object of the present invention is to provide an anticoagulant heparin oligosaccharide dimer.

[0021] The anticoagulant heparin oligosaccharide dimer, or a pharmaceutically acceptable salt thereof, has a structure shown in general formula I:

[0022]

[0023] Among them, R1 is sulfonyl (-SO3H) or acetyl (-COCH3); R2 and R3 are sulfonyl or hydrogen (-H); and n is an integer of 0-5.

[0024] Preferably according to the present invention, n=0, 1, or 2.

[0025] According to the preferred embodiment of the present invention, the benzene ring connected to the heparin oligosaccharide can also be replaced by a substituted phenyl ring, an aromatic heterocycle, a substituted aromatic heterocycle, a C 1- C5 alkyl or cycloalkyl.

[0026] According to the preferred embodiment of the present invention, the substituents of the substituted phenyl and substituted aromatic heterocycles are halogen, hydroxyl, nitro, trifluoromethyl, C 1- C5 alkyl or cycloalkyl.

[0027] Further preferably, the substituted phenyl group is selected from one of the following:

[0028]

[0029] Further preferably, the substituted aromatic heterocycle is selected from one of the following:

[0030]

[0031] More preferably, C 1- The alkyl group of C5 is

[0032]

[0033] More preferably, the cycloalkyl group is cyclohexane.

[0034] According to the preferred embodiment of the present invention, the anticoagulant heparin oligosaccharide dimer is specifically one of the following compounds:

[0035]

[0036]

[0037]

[0038] In formula I-1 to formula I-5, R1 is a sulfonyl group (-SO3H) or an acetyl group (-COCH3).

[0039] Preferably according to the present invention, the anticoagulant heparin oligosaccharide phenyl dimer molecule has significant anti-factor Xa activity and no obvious anti-factor IIa activity; its anti-factor Xa activity can be effectively neutralized by protamine, with a neutralization rate of >70%; it has pharmacokinetic characteristics similar to those of short-chain heparin oligosaccharides, a long half-life in vivo, and high bioavailability; it is not easy to cause HIT adverse reactions.

[0040] The second object of the present invention is to provide a method for preparing anticoagulant heparin oligosaccharide dimer by using a chemical enzymatic synthesis strategy.

[0041] A method for preparing an anticoagulant heparin oligosaccharide dimer, the method using a chemically synthesized GlcA-containing dimer intermediate as a starting material, and comprising the following steps a and b of glycosyltransferase catalyzed reaction repeated at least once and steps c, d, e, f, g of chemical enzymatic modification reaction combined with four or five of the steps;

[0042] Step a, under the catalysis of N-acetylglucosaminyltransferase (KfiA) or Heparosan synthase 2 (PmHS2), using UDP-GlcNTFA or UDP-GlcNAc as a glycosyl donor, the GlcNTFA or GlcNAc residue is transferred to the substrate phenyl di-O-glucoside or the two GlcAs at the non-reducing ends of the oligosaccharide intermediate dimer with the non-reducing end being GlcA through an α-1,4 glycosidic bond to generate a dimeric intermediate product with extended sugar chain;

[0043] Step b, under the catalysis of PmHS2 enzyme, UDP-GlcA is used as the glycosyl donor to react, and the GlcA residue is connected to the two glucosamines GlcNTFA or GlcNAc at the non-reducing end of the substrate by a β-1,4 glycosidic bond to generate an intermediate product of sugar chain extension;

[0044] Step c, the heparin oligosaccharide dimer intermediate is dissolved in an alkaline aqueous solution and placed on ice to detrifluoroacetylate (TFA) all the GlcNTFA residues of the sugar chain to convert them into GlcNH2, and then converted into GlcNS under the catalysis of N-sulfotransferase (NST) to obtain an N-sulfated heparin oligosaccharide dimer intermediate;

[0045] Step d, under the co-catalysis of C5-isomerase (C5-epi) and 2-O-sulfotransferase (2OST), all GlcA residues located between two GlcNS in the dimer sugar chain are converted into 2-O-sulfated iduronic acid (IdoA2S), thereby obtaining an IdoA2S-containing heparin oligosaccharide dimer intermediate;

[0046] Step e, under the catalysis of 2OST alone, all specific GlcA residues located between two GlcNS in the substrate are converted into 2-O-sulfated gluconic acid (GlcA2S);

[0047] Step f, under the joint catalysis of 6-O-sulfotransferase 1 and 6-O-sulfotransferase 3 (6OST1 and 6OST3), the 6-OH of all GlcNS or GlcNAc residues of the substrate sugar chain is sulfated to generate an intermediate product containing 6-O-sulfated heparin oligosaccharide dimers;

[0048] Step g, under the catalysis of 3-O-sulfotransferase 1 (3OST1), the 3-OH of GlcNS6S between GlcA and IdoA2S in the substrate sugar chain is sulfated (GlcNS6S3S) to obtain the anticoagulant heparin oligosaccharide dimer target compound.

[0049] According to the present invention, the preferred dimer intermediate containing GlcA is phenyl di-O-glucoside or substituted phenyl di-O-glucoside, aromatic heterocyclic di-O-glucoside, substituted aromatic heterocyclic di-O-glucoside, C 1- C5 alkyl bis O-gluconoside or cycloalkyl bis O-gluconoside.

[0050] According to the preferred embodiment of the present invention, the starting material phenyl di-O-glucoside is prepared by the following method:

[0051] Taking fully acetylated glucose as the starting material, acetylhydrazine is used to remove the terminal acetyl group to obtain an intermediate, the exposed anomeric hydroxyl group reacts with trichloroacetonitrile (CNCCl3) to obtain glycosyl trichloroacetimidate, which is then glycosylated with p-diphenol in the presence of a promoter to generate an intermediate, followed by alcoholysis to remove the acetyl group to obtain phenyl di-O-glucoside, and finally PhI(OAc)2 and Tempo are used to selectively oxidize C6-OH to obtain the target product.

[0052] The synthetic route is shown in the following formula II:

[0053]

[0054] Preferably, according to the present invention, the reaction solvent for removing the terminal acetyl group from the fully acetylated glucose 1 by using acetylhydrazine is anhydrous DMF, and the reaction is carried out at room temperature for 1 hour.

[0055] According to the preferred embodiment of the present invention, the exposed anomeric hydroxyl group of the intermediate 2 is reacted with trichloroacetonitrile (CNCCl3) at a temperature below 0°C for more than 3 hours, and the reaction solvent is a mixture of DBU and anhydrous DCM. The mixing ratio of the two is arbitrary.

[0056] According to the preferred embodiment of the present invention, the reaction of glycosyl trichloroacetimidate ester 3 and p-diphenol is carried out at -5°C for 1 hour using anhydrous DCM containing molecular sieves as solvent and BF3-Et2O as promoter, and the reaction solution is extracted with EA, vacuum dried, and recrystallized with methanol to obtain intermediate 4; intermediate 4 is treated with anhydrous MeOH-sodium methoxide at room temperature for more than 1 hour to remove the acetyl group, and then the solution is neutralized with an acidic resin to neutrality, filtered, vacuum dried and crystallized to obtain intermediate 5. The dosage of each reagent is carried out according to the prior art in the art.

[0057] Preferably, according to the present invention, intermediate 5 is selectively oxidized to C6-OH using PhI(OAc)2 and Tempo, and the solvent used is t-BuOH, DCM and H2O in a volume ratio of 4:4:1. The reaction is carried out at room temperature overnight, and then recrystallized from acetonitrile to obtain the target product phenyl di-O-glucoside 6.

[0058] The dosage of each reagent is carried out according to the prior art in the field.

[0059] The preferred method for preparing the anticoagulant heparin oligosaccharide phenyl dimer of the present invention uses phenyl di-O-glucoside 6 as a raw material and adopts the method of steps a, b and steps c, d, f, g to prepare the target compound I-1. The synthetic route is shown in Formula III:

[0060]

[0061] The chemoenzymatic synthesis route of I-1 can be simplified as: a→b→a→b→c→d→a→c or none→f→g.

[0062] According to the preferred embodiment of the present invention, the synthetic routes of Formula I-2 to Formula I-5 are as follows:

[0063] I-2: a→b→a→b→c→d→a→b→c→d→a→c or none→f→g;

[0064] I-3: a→b→a→b→c→e→a→b→c→d→a→c or none→f→g;

[0065] I-4: a→b→a→b→c→d→a→b→c→d→a→b→c→d→a→c or none→f→g;

[0066] I-5: a→b→a→b→c→d→f→a→b→a→b→c→d→a→c or none→f→g;

[0067] Preferably according to the present invention, the enzymes KfiA and PmHS2 are derived from Escherichia coli K5 and Pasteurella multocida, respectively, and are recombinantly expressed in Escherichia coli. The buffer used for the enzymatic sugar chain extension reaction is 50 mmol / L Tris-HCl, pH = 7.0-7.5, the reaction temperature is 20°C-37°C, and the enzymatic reaction solution is purified by reverse phase C18 or anion exchange column chromatography to obtain the product.

[0068] The amount of enzyme and substrate added and the reaction time are carried out according to the prior art.

[0069] Preferably according to the present invention, the heparinase modification enzymes NST, C5-epi, 2OST, 6OST1, 6OST3, and 3OST1 are obtained by recombinant expression in Escherichia coli, yeast or insect cells, the buffer for the catalytic reaction of each modification enzyme of NST, 2OST, 6OST1, 6OST3, and 3OST1 is 50 mmol / L 2-(N-morpholino)ethane sulfonic acid (MES), pH=7.0-7.5, the reaction temperature is 20°C-37°C, and 3'-phosphoadenosine-5'-phosphosulfate (PAPS) is used as a sulfate donor, and the enzymatic reaction solution is purified by anion exchange column chromatography to obtain a product.

[0070] The amount of enzyme and substrate added and the reaction time are carried out according to the prior art.

[0071] The third object of the present invention is to provide an application of a heparin oligosaccharide dimer containing an AT binding sequence, which has specific anti-Xa factor activity and no obvious anti-IIa activity, and its anticoagulant activity can be neutralized by protamine, and has better pharmacokinetics, and is used to prepare a potent and safe anticoagulant and antithrombotic drug.

[0072] An anticoagulant and antithrombotic pharmaceutical composition comprises the above-mentioned heparin oligosaccharide phenyl dimer molecule containing an AT binding sequence and one or more pharmaceutically acceptable carriers or excipients.

[0073] The ratio of heparin oligosaccharide phenyl dimer to the carrier or excipient is arbitrary.

[0074] The present invention uses two molecules of glucuronic acid covalently linked to the same benzene ring as starting materials for the first time, and successfully synthesizes an anticoagulant heparin oligosaccharide dimer containing an AT binding sequence by a chemical enzymatic method. The anticoagulant heparin oligosaccharide dimer not only has a strong anticoagulant activity, but most importantly, it exhibits a protamine neutralization property similar to that of long-chain heparin molecules, and an ideal pharmacokinetic characteristic similar to that of short-chain molecules. In addition, the risk of inducing adverse reactions such as HIT is low, and the preparation steps are few, with a minimum of only 9 steps. The anticoagulant oligosaccharide dimer can be developed into a new generation of safer and higher-quality innovative anticoagulant drugs with independent intellectual property rights, and has important application value.

[0075] The technical features and advantages of the present invention are as follows:

[0076] 1. The present invention confirms for the first time that new dimer molecules of different heparin oligosaccharides (hexasaccharide, octasaccharide, decasaccharide) containing AT binding sequences can be successfully prepared by using phenyl di-O-gluconoside containing 2 GlcAs as the starting material through 9 to 18 steps of chemical enzymatic reaction.

[0077] 2. The chromogenic substrate method showed that the novel heparin oligosaccharide dimer containing AT binding sequence had significant anti-factor Xa activity and no significant anti-factor IIa activity, which was the first time to confirm that the two AT binding sequences in the heparin oligosaccharide dimer could activate AT without interfering with each other, and its half inhibitory molar concentration (IC50) for inhibiting factor Xa was 2.37kcal / cm3. 50 ) was significantly lower than the positive control fondaparinux sodium and the long-chain heparin dodecasaccharide molecule reported by Jian Liu.

[0078] 3. The specific anti-factor Xa activity of the novel heparin oligosaccharide phenyl dimer containing an AT binding sequence of the present invention can be efficiently neutralized by protamine, with a neutralization rate of >70%, which is comparable to that of long-chain unfractionated heparin UFH and reported heparin dodecasaccharides, while the anti-factor Xa activity of commercially available fondaparinux sodium can hardly be neutralized by protamine, and the existing reported anticoagulant heparin hexasaccharides, octasaccharides, and decasaccharides can not be neutralized by protamine. Therefore, the heparin oligosaccharide phenyl dimer of the present invention has similar properties to long-chain heparin molecules of heparin dodecasaccharides and above, and can be neutralized by generating a higher affinity interaction with protamine.

[0079] 4. The heparin oligosaccharide dimer of the present invention has ideal pharmacokinetic characteristics. For example, the in vivo half-life of compound I-1-1 is comparable to that of commercially available fondaparinux sodium, and is significantly superior to animal-derived heparin and the currently reported heparin dodecasaccharide molecules.

[0080] 5. The sugar chains and modified groups outside the AT binding sequence in the heparin oligosaccharide dimer structure of the present invention have little effect on the anti-Xa activity, but have a significant effect on the neutralization efficiency and pharmacokinetic characteristics of protamine.

[0081] 6. The heparin oligosaccharide dimer of the present invention can be used to prepare a cost-effective, higher-quality, safer, and more potent anticoagulant and antithrombotic drug. BRIEF DESCRIPTION OF THE DRAWINGS

[0082] Figure 1 It is the phenyl bis O-glucoside 6 prepared in Example 1 1 H NMR spectrum;

[0083] Figure 2 1 is the HPLC chromatogram (A) and mass spectrum (B) of the heparin hexasaccharide phenyl dimer I-1-1 prepared in Example 5;

[0084] Figure 3 The heparin hexasaccharide phenyl dimer I-1-1 prepared in Example 5 1 H NMR (A) and HSQC (B) spectra;

[0085] Figure 4 The in vitro anti-Xa factor of the heparin hexasaccharide phenyl dimer I-1-1 prepared in Example 5;

[0086] Figure 5 The neutralizing effect of protamine on the anticoagulant activity of the heparin hexasaccharide dimer I-1-1 of Example 5 in vitro.

[0087] Figure 6 The in vivo pharmacokinetic characteristics of the heparin hexasaccharide phenyl dimer I-1-1 prepared in Example 5. DETAILED DESCRIPTION

[0088] The present invention is further described below in conjunction with specific embodiments, but the protection scope of the present invention is not limited thereto. The drugs and reagents involved in the embodiments are all common commercially available products unless otherwise specified.

[0089] Example 1: Chemical Synthesis of Phenyl Bis-O-Gluconoside 6

[0090] Compound 1 (1 g, 2.6 mmol) and AcOH / NH2-NH2 (1.4 equiv. 3.6 mmol, 330 mg) were dissolved in 5 ml of anhydrous DMF and reacted at room temperature for 1 h. After the reaction, the reaction solution was diluted with EA, and the organic layer was washed with H2O and saturated brine, respectively, and the residue was dried in vacuo. Purification by silica gel column chromatography (PE:EA=2:1) ​​gave 752 mg of colorless oily liquid 2, with a yield of 84.3%.

[0091] Compound 2 (752 mg, 2.16 mmol) was dissolved in 5 ml of anhydrous DCM, and CNCCl3 (3 equiv. 6.5 mmol, 0.65 ml) and DBU (0.2 equiv. 0.43 mmol) were added in sequence at low temperature, and the mixture was reacted at the same temperature for 3 h. After the reaction, the reaction solution was directly vacuum dried to obtain a filter residue, which was purified by silica gel column chromatography (PE: EA = 4: 1) to obtain 893 mg of colorless oily liquid 3, with a yield of 83.8%.

[0092] Compound 3 (893 mg, 1.8 mmol, 2.2 equiv.) and p-diphenol (0.82 mmol, 83 mg) were dissolved in 10 ml of anhydrous DCM containing an appropriate amount of molecular sieves, and BF3-Et2O (4 equiv. 3.28 mmol, 0.4 ml) was added at -5°C, and the reaction was continued at this temperature for 1 h. After the reaction was completed, the reaction solution was diluted with EA, and the organic layer was washed with saturated sodium bicarbonate solution, water, and saturated brine in sequence. The washed organic layer was vacuum dried, and the residue was recrystallized from methanol to obtain 462 mg of white solid compound 4, with a yield of 73%. 1 H NMR(400MHz,Chloroform-d)δ6.91(d,J=4.6Hz,4H),5.30–5.11(m,6H),4.98(dd,J=7.4,3.6Hz,2H),4.26(dd,J=1 2.4, 5.2Hz, 2H), 4.15 (dt, J = 12.2, 2.8Hz, 2H), 3.80 (ddt, J = 10.0, 5.2, 2.4Hz, 2H), 2.04 (dt, J = 13.2, 4.8Hz, 24H).

[0093] Compound 4 (462 mg, 0.6 mmol) and sodium methoxide (0.1 equiv. 3 mg) were dissolved in 10 ml of anhydrous MeOH and reacted at room temperature for 1 h. After the reaction was completed, an acidic resin was added and stirred for 10 min. The reaction solution was neutralized to neutrality, filtered, and most of the solvent was dried under vacuum. The remaining reaction solution was placed in a refrigerator for precipitation to obtain 247 mg of white solid compound 5 with a yield of 95%.

[0094] Compound 5 (247 mg, 0.57 mmol), PhI(OAc)2 (8 equiv. 4.6 mmol, 1.5 g) and Tempo (4 equiv. 2.3 mmol, 355 mg) were dissolved in 18 ml of a mixed solvent (t-BuOH: DCM: H2O = 4:4:1) and reacted overnight at room temperature. After the reaction was completed, the reaction solution was diluted with EA, the organic layer was washed with water, the aqueous layer was spin-dried, and the residue was vacuum dried and recrystallized with acetonitrile to obtain 162 mg of a white solid compound 6 with a yield of 62%.

[0095] The synthetic route is shown in the following formula II:

[0096]

[0097] Compound 6 1 H NMR spectrum is shown in Figure 1 .

[0098] Important 1H NMR (400 MHz, D2O) data were δ 7.13 (dd, J = 2.8, 1.8 Hz, 4H), 5.16–5.06 (m, 2H), 4.10–4.00 (m, 2H), 3.72–3.56 (m, 6H).

[0099] Example 2: Enzymatic Synthesis of Heparin Pentasaccharide Backbone Dimer 8

[0100] Weigh 50 mg of phenyl di-O-glucoside 6 and dissolve it in ~50 mL 50 mmol / LTris-HCl buffer (containing 6 mmol / LMnCl2, pH = 7.2), add 2.2 times the equivalent of substrate UDP-GlcNTFA and 2.5 mL KfiA enzyme, stir at room temperature overnight, and detect the reaction by PAMN-HPLC. The chromatographic conditions are 0→100% KH2PO4 gradient elution within 45 min, flow rate of 0.5 mL / min, and detection wavelength of 280 nm. When the reaction yield is ≥99%, adjust the pH to 2-3 with trifluoroacetic acid (TFA) to stop the reaction, and use C 18 The product was purified by chromatography column (3×50cm) and eluted with methanol-water containing 0.1% TFA to obtain the target component. The obtained product was placed in 50mL of the same buffer as above, and 2.2 equivalents of UDP-GlcA and 3mL PmHS2 enzyme were added at the same time, and stirred at room temperature overnight. PAMN-HPLC detection reaction was performed until the yield was ≥99%, and intermediate 7 was purified by C18 chromatography column. Repeat the above KfiA and PmHS2 enzyme reactions to obtain heparin pentasaccharide backbone dimer 8, and its molecular weight measured by ESI was consistent with the theory.

[0101] The synthetic route is shown in the following formula IV:

[0102]

[0103] Example 4: Chemoenzymatic Synthesis of Heparin Pentasaccharide Dimer 10 Containing IdoA2S

[0104] The pentasaccharide backbone dimer 8 was dissolved in 100 mL of deionized water, placed on ice, and 0.5 mol / L LiOH solution was added dropwise to pH = 12, and the mixture was placed in an ice bath for 2 h. The reaction progress was detected by PAMN-HPLC. After the reaction, the pH was adjusted to neutral with glacial acetic acid, and an appropriate amount of 1 mol / L MES solution (pH = 7.4) was added to make the final concentration of 50 mmol / L. At the same time, 4.4 times the equivalent of PAPS and 3 mL of NST enzyme were added, and the mixture was stirred at room temperature overnight. The reaction was detected by PAMN-HPLC. When the reaction yield was > 95%, the pH was adjusted to 4-5 with acetic acid to terminate the reaction, and the mixture was purified using a Q Sepharose column (1×20 cm) at a flow rate of 3 mL / min, with a gradient elution of 0→100% buffer (pH = 5) containing 1 mol / L NaCl and 50 mmol / L NaAc, and the detection wavelengths were 260 nm and 280 nm. The target component was collected, desalted, and dried to obtain the N-sulfated product 9. ESI-MS measured its molecular weight as 2130.22 Da.

[0105] Take the above product 9, add 2mmol / L CaCl2 and an appropriate amount of enzyme C5-epi to a 50mmol / L MES buffer at pH = 7.0-7.4, adjust the reaction volume to 100mL, and react in a 37°C water bath for 2h. Then add about 2.5 times the equivalent of PAPS, additional C5-epi and sufficient 2OST enzyme, and react at room temperature overnight. PAMN-HPLC detects the reaction, and enzymes or PAPS are added as needed until the reaction is completed. The reaction solution is purified with a Q-Sepharose strong anion column (1×20cm) to obtain heparin pentasaccharide dimer 10. ESI-MS determined its molecular weight to be 2290.20Da.

[0106] The synthetic route is shown in the following formula V:

[0107]

[0108] Example 5: Chemoenzymatic preparation of heparin hexasaccharide phenyl dimer I-1-1

[0109] Pentasaccharide dimer 10 was used as substrate, and the sugar chain was extended by KfiA enzyme catalyzed as described in Example 1. The reaction solution was purified by Q-Sepharose strong anion column (1 cm×20 cm), and the obtained product was subjected to chemical enzymatic N-sulfation modification as described in Example 4 to obtain heparin hexasaccharide dimer 11. The molecular weight was determined by ESI-MS to be 2772.41 Da, which was consistent with the theoretical value.

[0110] The hexasaccharide phenyl dimer 11 was placed in a MES buffer with a pH of 7.0-7.5 and a 50 mmol / L buffer. 7 times the equivalent of PAPS, 4 mL of 6OST1 and 4 mL of 6OST3 enzyme were added, and the reaction volume was adjusted to 140 mL. The reaction was allowed to react overnight in a water bath at 37°C. The reaction progress was detected by SAX-HPLC, and enzyme or PAPS was added as needed. The chromatographic conditions were: a flow rate of 1 mL / min, a gradient elution of 0→100% eluent B (50 mmol / L NaAc+2 mol / L NaCl, pH=5), and a detection wavelength of 260 nm and 280 nm. When the reaction yield was >99%, the reaction was terminated by adjusting the pH to 4-5 with dilute acetic acid, and the enzyme was removed by freezing and thawing in a refrigerator at -20°C without purification. The solution pH was adjusted to 7.0-7.5, and about 2.5 times the equivalent of PAPS and 5 mL of 3OST1 enzyme were added. The reaction volume was adjusted to 200 mL, and the reaction was allowed to react overnight in a water bath at 37°C. The PAMN-HPLC reaction was performed until the substrate modification rate was above 99%. The reaction solution was adjusted to pH 4-5 with dilute acetic acid and then purified with a Q-Sepharose strong anion column (1 cm × 10 cm) to obtain the target heparin hexasaccharide dimer I-1-1, with a purity of above 92% ( Figure 2 A). ESI-MS determined its molecular weight to be 3411.99 Da ( Figure 2 B), which is consistent with the theoretical value. 1 H NMR and HSQC ( Figure 3 ) to characterize its structure.

[0111] The synthetic route is shown in the following formula VI:

[0112]

[0113] Test Example 1: Determination of in vitro anticoagulant activity of heparin hexasaccharide phenyl dimer I-1-1

[0114] The IC value of the anti-FⅩa activity of the heparin hexasaccharide phenyl dimer I-1-1 prepared in Example 5 was measured by the chromogenic substrate method. 50 The value was 7.2nmol / L (28.15ng / mL). Under the same conditions, the IC values ​​of unfractionated heparin (UFH) and fondaparinux sodium were measured. 50 The values ​​were 378.3 ng / mL and 10.8 nmol / L (18.63 ng / mL), which are the IC values ​​of I-1-1 anti-FⅩa activity in terms of molar concentration. 50 The value was significantly lower than that of fondaparinux, indicating that it is a potent Xa inhibitor. Figure 4As shown. At the same time, the target compound I-1-1 was similar to fondaparinux sodium and had no significant anti-factor IIa activity as determined by the chromogenic substrate method (data omitted). Therefore, the heparin hexasaccharide dimer I-1-1 prepared by the present invention is a specific inhibitor of factor Xa, and because the two AT binding sequences contained in it can activate AT without interfering with each other, it is superior to fondaparinux sodium containing a single AT binding sequence and the heparin dodecasaccharide reported by Jian Liu, with a half inhibition molar concentration (IC 50 ) was significantly lower than the positive control fondaparinux sodium and the long-chain heparin dodecasaccharide molecule reported by Jian Liu.

[0115] Experimental Example 2: Determination of the neutralization effect of protamine on the anticoagulant activity of heparin hexasaccharide phenyl dimer I-1-1

[0116] The effect of adding different concentrations of protamine on the anti-FⅩa activity of the heparin hexasaccharide dimer I-1-1 of Example 5 was determined by the chromogenic substrate method. The results are as follows: Figure 5 ,Depend on Figure 5 It can be seen that, similar to UFH, the in vitro anti-FⅩa activity of the heparin hexasaccharide phenyl dimer I-1-1 is almost completely reversed by protamine. Therefore, the heparin hexasaccharide phenyl dimer I-1-1 prepared by the present invention is a new type of heparin analogue whose anticoagulant activity can be neutralized by protamine.

[0117] Experimental Example 3: In vivo pharmacokinetic characteristics of heparin hexasaccharide phenyl dimer I-1-1

[0118] The chromogenic substrate method was used to establish a standard curve using a low molecular weight heparin standard as an example, and the titers of fondaparinux sodium and heparin hexasaccharide dimer I-1-1 were measured to be 1290.9 IU / mg and 1121.5 IU / mg, respectively. Fondaparinux sodium and heparin hexasaccharide dimer I-1-1 were subcutaneously injected into Wister male rats weighing 200±20g (n≥3) at a dose of 300 IU / kg. Blood samples were collected from the jugular vein of rats at 0, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 8, 12, and 24h (subject to the actual blood collection time). The blood samples were centrifuged at 5000 r / min for 15 minutes, and the supernatant was taken to determine the anti-Xa factor activity using the above method. The residual concentrations of fondaparinux sodium and heparin hexaglycophenyl dimer I-1-1 in rats were calculated, and the drug concentration-time curve was drawn. Figure 6 It can be seen that the curves of fondaparinux sodium and the heparin hexasaccharide phenyl dimer I-1-1 of the present invention are very similar. Further processing the data using DAS 2.0, the t of the heparin hexasaccharide phenyl dimer I-1-1 can be obtained. 1 / 2 The t of fondaparinux was 2.269 h, slightly longer than that of fondaparinux. 1 / 2It is 2.166h, indicating that the half-life of heparin hexasaccharide phenyl dimer I-1-1 is excellent.

Claims

1. Anticoagulant heparin oligosaccharide dimer having the structure shown in general formula I: I in, R1 is sulfonyl (-SO3H) or acetyl (-COCH3); R2 and R3 are sulfonyl or hydrogen (-H); n is 0, 1 or 2.

2. The anticoagulant heparin oligosaccharide dimer according to claim 1, characterized in that: The anticoagulant heparin oligosaccharide dimer is specifically one of the following compounds: I-1, I-2, I-3, I-4, I-5, In formula I-1 to formula I-5, R1 is a sulfonyl group (-SO3H) or an acetyl group (-COCH3).

3. The method for preparing the anticoagulant heparin oligosaccharide dimer according to claim 1, which uses a chemically synthesized dimer intermediate containing GlcA as a starting material, and is a method in which the glycosyltransferase catalyzed reaction of steps a and b is repeated at least once and four or five of the steps c, d, e, f, and g are combined with the chemical enzymatic modification reaction; Step a, in N - Under the catalysis of acetylglucosaminyltransferase (KfiA) or heparosan synthase 2 (PmHS2), with UDP-GlcNTFA or UDP-GlcNAc as the glycosyl donor, the GlcNTFA or GlcNAc residue is transferred to the two GlcAs at the non-reducing ends of the substrate phenyl di-O-glucoside or the oligosaccharide intermediate dimer with GlcA at the non-reducing end through an α-1,4 glycosidic bond to generate a dimeric intermediate product with extended sugar chain; Step b, under the catalysis of PmHS2 enzyme, UDP-GlcA is used as the glycosyl donor to react, and the GlcA residue is connected to the two glucosamines GlcNTFA or GlcNAc at the non-reducing end of the substrate by a β-1,4 glycosidic bond to generate an intermediate product of sugar chain extension; Step c, the heparin oligosaccharide dimer intermediate is dissolved in an alkaline aqueous solution and placed on ice to detrifluoroacetylate all the GlcNTFA residues of the sugar chain to convert them into GlcNH2, and then N -sulfotransferase (NST) catalyzes the conversion of NST into GlcNS to obtain N -Sulfated heparin oligosaccharide dimer intermediate; Step d, in C5-isomerase (C5-epi), 2- O - Under the co-catalysis of sulfotransferase (2OST), all GlcA residues located between two GlcNS in the dimer sugar chain are converted into 2-O-sulfated iduronic acid (IdoA2S), obtaining an IdoA2S-containing heparin oligosaccharide dimer intermediate; Step e: Under the catalysis of 2OST alone, all specific GlcA residues located between two GlcNS in the substrate are converted into 2-O-sulfated gluconic acid (GlcA2S); Step f, under the joint catalysis of 6-O-sulfotransferase 1 and 6-O-sulfotransferase 3 (6OST1 and 6OST3), the 6-OH of all GlcNS or GlcNAc residues of the substrate sugar chain is sulfated to generate an intermediate product containing 6-O-sulfated heparin oligosaccharide dimers; Step g, under the catalysis of 3-O-sulfotransferase 1 (3OST1), the 3-OH of GlcNS6S between GlcA and IdoA2S in the substrate sugar chain is sulfated (GlcNS6S3S) to obtain the anticoagulant heparin oligosaccharide dimer target compound.

4. The preparation method according to claim 3, characterized in that: The dimer intermediate containing GlcA is phenyl di-O-glucoside or substituted phenyl di-O-glucoside, aromatic heterocyclic di-O-glucoside, substituted aromatic heterocyclic di-O-glucoside, C 1- C5 alkyl bis O-gluconoside or cycloalkyl bis O-gluconoside; The starting material phenyl di-O-glucoside was prepared as follows: Taking fully acetylated glucose as the starting material, acetylhydrazine was used to remove the terminal acetyl group to obtain an intermediate, and the naked anomeric hydroxyl group was reacted with trichloroacetonitrile (CNCCl3) to obtain glycosyl trichloroacetimidate, which was then glycosylated with p-diphenol in the presence of a promoter to generate an intermediate, followed by alcoholysis to remove the acetyl group to obtain phenyl di-O-glucoside, and finally PhI(OAc)2 and Tempo were used to selectively oxidize C6-OH to obtain the target product.

5. The preparation method according to claim 4, characterized in that: The reaction solvent for fully acetylated glucose 1 to remove the terminal acetyl group by acetylhydrazine was anhydrous DMF, and the reaction was carried out at room temperature for 1 h; The exposed anomeric hydroxyl group of the intermediate reacts with trichloroacetonitrile (CNCCl3) at a temperature below 0°C for more than 3 hours, and the reaction solvent is a mixture of DBU and anhydrous DCM; The reaction of glycosyl trichloroacetimidate 3 with p-diphenol was carried out at -5°C for 1 h using anhydrous DCM containing molecular sieves as solvent and BF3-Et2O as promoter. The reaction solution was extracted with EA, vacuum dried, and recrystallized with methanol to obtain intermediate 4. Intermediate 4 was treated with anhydrous MeOH-sodium methoxide at room temperature for more than 1 h to remove the acetyl group, and then the solution was neutralized with an acidic resin to neutrality, filtered, vacuum dried, and crystallized to obtain intermediate 5. Intermediate 5 was selectively oxidized to C6-OH using PhI(OAc)2 and Tempo. The solvent used was t-BuOH, DCM and H2O in a volume ratio of 4:4:

1. The reaction was carried out at room temperature overnight and then recrystallized from acetonitrile to obtain the target product phenyl di-O-gluconoside 6.

6. The preparation method according to claim 4, characterized in that: Using phenyl di-O-glucoside 6 as raw material, the target compound I-1 was prepared by the method of steps a, b and steps c, d, f, g. The synthetic route is shown in Formula III: Formula III.

7. The preparation method according to claim 3, characterized in that: The synthetic routes of formula I-2 to formula I-5 are as follows: I-2: a→b→a→b→c→d→a→b→c→d→a→c or none→ f→g; I-3: a→b→a→b→c→e→a→b→c→d→a→c or none→ f→g; I-4: a→b→a→b→c→d→a→b→c→d→a→b→c→d→a→c or none→f→g; I-5: a→b→a→b→c→d→f→a→b→a→b→c→d→a→c or none→f→g.

8. The preparation method according to claim 3, characterized in that: The enzymes KfiA and PmHS2 are derived from Escherichia coli K5 and Pasteurella multocida, respectively. Pasteurella multocida ), recombinantly expressed in E. coli, the buffer used for enzymatic sugar chain extension reaction was 50 mmol / L Tris-HCl, pH=7.0~7.5, the reaction temperature was 20℃~37℃, and the enzymatic reaction solution was purified by reverse phase C18 or anion exchange column chromatography to obtain the product; The heparinase modification enzymes NST, C5-epi, 2OST, 6OST1, 6OST3, and 3OST1 are obtained by recombinant expression in Escherichia coli, yeast, or insect cells. The buffer for the catalytic reaction of each modification enzyme of NST, 2OST, 6OST1, 6OST3, and 3OST1 is 50 mmol / L 2-( N -morpholino)ethanesulfonic acid (MES), pH=7.0~7.5, reaction temperature 20℃~37℃, and 3'-phosphoadenosine-5'-phosphosulfate (PAPS) as the sulfate donor, the enzymatic reaction solution is purified by anion exchange column chromatography to obtain the product.

9. Use of the anticoagulant heparin oligosaccharide dimer according to claim 1 for preparing potent anticoagulant and antithrombotic drugs.